Clearside Biomedical Future Growth
Future criteria checks 2/6
Clearside Biomedical is forecast to grow earnings and revenue by 6% and 64.7% per annum respectively while EPS is expected to grow by 26.9% per annum.
Key information
6.0%
Earnings growth rate
26.9%
EPS growth rate
Pharmaceuticals earnings growth | 23.9% |
Revenue growth rate | 64.7% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 05 Dec 2024 |
Recent future growth updates
Recent updates
Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation
Nov 06We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate
Jun 24Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation
Nov 12Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)
Aug 11Clearside Biomedical Q2 2022 Earnings Preview
Aug 08Clearside Biomedical: A Pivotal 2022 Ahead
Apr 13Clearside's Safety Data In Wet AMD And Emphasis On SCS Microinjector Make It Great Speculative Play
Dec 22Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business
Sep 30Clearside's Value Proposition Is Far From Clear
Aug 07We Think Clearside Biomedical (NASDAQ:CLSD) Can Easily Afford To Drive Business Growth
Jun 17Clearside Biomedical climbs after positive results from early-stage wet AMD trial
Jun 15Clearside Biomedical resubmits eye treatment XIPERE NDA
May 03If You Had Bought Clearside Biomedical (NASDAQ:CLSD) Shares A Year Ago You'd Have Earned 45% Returns
Feb 16Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 11 | -57 | -54 | N/A | 5 |
12/31/2025 | 3 | -46 | -38 | N/A | 7 |
12/31/2024 | 2 | -36 | -8 | N/A | 7 |
9/30/2024 | 8 | -32 | -20 | -19 | N/A |
6/30/2024 | 8 | -33 | -20 | -19 | N/A |
3/31/2024 | 8 | -35 | -20 | -19 | N/A |
12/31/2023 | 8 | -32 | -20 | -18 | N/A |
9/30/2023 | 2 | -37 | -26 | -24 | N/A |
6/30/2023 | 2 | -36 | -26 | -24 | N/A |
3/31/2023 | 1 | -35 | -25 | -24 | N/A |
12/31/2022 | 1 | -33 | -14 | -13 | N/A |
9/30/2022 | 27 | -5 | -3 | -3 | N/A |
6/30/2022 | 29 | -2 | 0 | 0 | N/A |
3/31/2022 | 30 | 0 | -1 | -1 | N/A |
12/31/2021 | 30 | 0 | -11 | -11 | N/A |
9/30/2021 | 4 | -25 | -20 | -20 | N/A |
6/30/2021 | 4 | -23 | -20 | -20 | N/A |
3/31/2021 | 4 | -23 | -16 | -16 | N/A |
12/31/2020 | 8 | -18 | -13 | -13 | N/A |
9/30/2020 | 10 | -14 | -7 | -7 | N/A |
6/30/2020 | 7 | -18 | -10 | -10 | N/A |
3/31/2020 | 6 | -18 | -17 | -17 | N/A |
12/31/2019 | 2 | -31 | -27 | -27 | N/A |
9/30/2019 | 0 | -49 | -53 | -53 | N/A |
6/30/2019 | 0 | -67 | -67 | -67 | N/A |
3/31/2019 | 0 | -82 | -76 | -76 | N/A |
12/31/2018 | 0 | -83 | -79 | -79 | N/A |
9/30/2018 | 0 | -78 | -70 | -70 | N/A |
6/30/2018 | 0 | -72 | N/A | -64 | N/A |
3/31/2018 | 0 | -65 | N/A | -56 | N/A |
12/31/2017 | 0 | -59 | N/A | -51 | N/A |
9/30/2017 | 0 | -52 | N/A | -42 | N/A |
6/30/2017 | 0 | -39 | N/A | -35 | N/A |
3/31/2017 | 0 | -31 | N/A | -29 | N/A |
12/31/2016 | 1 | -26 | N/A | -23 | N/A |
9/30/2016 | 1 | -21 | N/A | -20 | N/A |
6/30/2016 | 1 | -19 | N/A | -17 | N/A |
3/31/2016 | 1 | -19 | N/A | -15 | N/A |
12/31/2015 | N/A | -18 | N/A | -14 | N/A |
9/30/2015 | N/A | -15 | N/A | -13 | N/A |
6/30/2015 | N/A | -15 | N/A | -13 | N/A |
3/31/2015 | N/A | -12 | N/A | -11 | N/A |
12/31/2014 | N/A | -10 | N/A | -9 | N/A |
9/30/2014 | N/A | -9 | N/A | -8 | N/A |
6/30/2014 | N/A | -8 | N/A | -7 | N/A |
3/31/2014 | N/A | -8 | N/A | -7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CLSD is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CLSD is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CLSD is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CLSD's revenue (64.7% per year) is forecast to grow faster than the US market (9.1% per year).
High Growth Revenue: CLSD's revenue (64.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CLSD's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 13:28 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Clearside Biomedical, Inc. is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Daniil Gataulin | Chardan Capital Markets, LLC |
Yi Chen | H.C. Wainwright & Co. |
Esther Lannie Hong | Janney Montgomery Scott LLC |